Alzheimer’s Research News: Biogen’s amyloid beta-directed ...
2
‘Dementia Care, let’s get it right’ Quarterly Newsletter Summer 2021 23 rd National Care Awards 2021 – Careinfo Friday 19 th November live event 2021 in London. click the link for categories and how to enter A new booklet has been released to provide information and advice for family and friends about eating and drinking as dementia progresses towards end of life: www.ucl.ac.uk/psychiatry/nutrition A resource written by Martin Robertson. Diagnosed with PCA (Posterior Cortical Atrophy) Martin has written this resource to help those with a dementia diagnosis wishing to continue in employment: Work after a diagnosis of dementia | Life Changes Trust Stay up to date with Young Onset Dementia news and support: https://www.youngdementiauk.org Alzheimer’s Research News: A new drug, Biogen’s aducanumab (brand name Aduhelm) has been approved by the FDA (America). The medication is an amyloid beta-directed monoclonal antibody that reduces the plaques that build up in the brains of people with Alzheimer’s disease. Administered through an infusion through the arm, it is the first drug that actively treats Alzheimer’s and slows progression and the first new treatment approved in 20 years. The UK is set to make its own own ruling on use of the drug in the autumn. The medication has promise, but it is necessary to identify the onset of Alzheimer’s as early as possible so that plaques can be reduced before they cause irreversible damage to brain cells. For more information: Alzheimer's Research UK - the UK's leading Alzheimer's research charity (alzheimersresearchuk.org)
Transcript of Alzheimer’s Research News: Biogen’s amyloid beta-directed ...
‘Dementia Care, let’s get it right’
Quarterly Newsletter Summer 2021
23rd National Care Awards 2021 – CareinfoFriday 19th November live event 2021 in London.click the link for categories and how to enter
A new booklet has been released to provide information and advice for family and friends about eating and drinking as dementia progresses towards end of life:www.ucl.ac.uk/psychiatry/nutrition
A resource written by Martin Robertson. Diagnosed with PCA (Posterior Cortical Atrophy) Martin has written this resource to help those with a dementia diagnosis wishing to continue in employment:Work after a diagnosis of dementia | Life Changes Trust
Stay up to date with Young Onset Dementia news and support:https://www.youngdementiauk.org
Alzheimer’s Research News:A new drug, Biogen’s aducanumab (brand name Aduhelm) has been approved by the FDA (America). The medication is anamyloid beta-directed monoclonal antibody that reduces the plaques that build up in the brains of people with Alzheimer’sdisease. Administered through an infusion through the arm, it is the first drug that actively treats Alzheimer’s and slowsprogression and the first new treatment approved in 20 years. The UK is set to make its own own ruling on use of the drugin the autumn. The medication has promise, but it is necessary to identify the onset of Alzheimer’s as early as possible sothat plaques can be reduced before they cause irreversible damage to brain cells. For more information:Alzheimer's Research UK - the UK's leading Alzheimer's research charity (alzheimersresearchuk.org)
‘Dementia Care, let’s get it right’
Quarterly Newsletter Summer 2021
23rd National Care Awards 2021 – CareinfoFriday 19th November live event 2021 in London.click the link for categories and how to enter
A new booklet has been released to provide information and advice for family and friends about eating and drinking as dementia progresses towards end of life:www.ucl.ac.uk/psychiatry/nutrition
A resource written by Martin Robertson. Diagnosed with PCA (Posterior Cortical Atrophy) Martin has written this resource to help those with a dementia diagnosis wishing to continue in employment:Work after a diagnosis of dementia | Life Changes Trust
Stay up to date with Young Onset Dementia news and support:https://www.youngdementiauk.org
Alzheimer’s Research News:A new drug, Biogen’s aducanumab (brand name Aduhelm) has been approved by the FDA (America). The medication is anamyloid beta-directed monoclonal antibody that reduces the plaques that build up in the brains of people with Alzheimer’sdisease. Administered through an infusion through the arm, it is the first drug that actively treats Alzheimer’s and slowsprogression and the first new treatment approved in 20 years. The UK is set to make its own own ruling on use of the drugin the autumn. The medication has promise, but it is necessary to identify the onset of Alzheimer’s as early as possible sothat plaques can be reduced before they cause irreversible damage to brain cells. For more information:Alzheimer's Research UK - the UK's leading Alzheimer's research charity (alzheimersresearchuk.org)
